BPC-157

Overview

Body Protection Compound-157 (BPC-157) is a synthetic pentadecapeptide (15 amino acids) derived from a protective protein found in human gastric juice. Originally isolated by researchers studying gastroprotective mechanisms, it has become one of the most extensively studied peptides in preclinical tissue-repair research. Its chemical stability at physiological pH and oral bioavailability in animal models distinguish it from many other research peptides.

Mechanism of Action

BPC-157 appears to exert its effects through multiple overlapping pathways. It modulates nitric oxide (NO) synthesis — both upregulating eNOS in vascular tissue and attenuating excessive iNOS activity in inflammatory states. It upregulates growth factor expression including VEGF and EGR-1, promoting angiogenesis and fibroblast proliferation. BPC-157 also interacts with dopaminergic and serotonergic neurotransmitter systems, which may account for reported neuroprotective and mood-stabilising effects in rodent models. Collagen synthesis and tendon-to-bone insertion remodelling are enhanced through FAK-paxillin pathway activation.

Key Research Areas

The majority of published research is preclinical (rodent models). Key areas include: (1) Tendon and ligament healing — multiple studies report accelerated Achilles and rotator-cuff repair. (2) Muscle repair — blunt-force and crush-injury models show faster functional recovery. (3) Bone healing — fracture models demonstrate improved mineralisation rates. (4) Gastrointestinal protection — robust evidence for protection against NSAID-induced gastric lesions, IBD models, and fistula closure. (5) CNS and peripheral nerve repair — spinal cord crush, sciatic nerve transection, and traumatic brain injury models. (6) Corneal tissue repair. As of 2025 there are no completed Phase II or III human clinical trials.

Observed Benefits

In animal studies the most consistently observed benefits are: accelerated soft-tissue and tendon healing (often 30-50% faster in injury models); gastroprotection against NSAID, alcohol, and stress-induced ulcers; reduced systemic inflammation markers; partial reversal of dopamine-depletion behaviours in movement-disorder models; improved peripheral nerve conduction after crush injury; and cytoprotective effects in liver and heart ischaemia-reperfusion models. These results have not yet been replicated in controlled human trials.

Half-Life and Stability

BPC-157 has a very short systemic half-life, estimated at under 30 minutes in rodent pharmacokinetic studies. Despite this, studies show sustained biological effects that outlast plasma clearance, suggesting local tissue depot activity or downstream gene-expression changes. The peptide is notably stable across a wide pH range (1-11), consistent with its survival in gastric acid and its documented oral efficacy in animal models. Lyophilised powder is stable at -20 degrees C for extended periods; reconstituted solution should be stored at 4 degrees C and used within 2-4 weeks.

Research Limitations

Several important caveats apply to the BPC-157 literature: (1) Almost all evidence is from rodent models; direct extrapolation to humans carries significant uncertainty. (2) No completed randomised controlled human trials exist as of 2025. (3) Many studies originate from a single Croatian research group (Sikiric et al.), creating a concentration-of-source bias. (4) Optimal human dosing, administration route, and cycle length are unknown. (5) Long-term safety data in humans is absent. (6) BPC-157 is not approved by the FDA, EMA, or any major regulatory body for therapeutic use. It is not scheduled as a controlled substance in most countries but is prohibited in sport by WADA. BPC-157 is not FDA approved for any medical use and is classified as a Category 2 bulk drug substance, meaning it cannot be compounded by commercial pharmacies.

Common Research Stacking

In preclinical and anecdotal research contexts, BPC-157 is frequently combined with: TB-500 (Thymosin Beta-4 fragment) for complementary musculoskeletal repair — different mechanisms targeting actin polymerisation and cell migration; KPV or other anti-inflammatory peptides for GI protocols; and GHRPs such as Ipamorelin where systemic recovery is the research objective. The BPC-157 + TB-500 pairing is the most studied combination, with rodent studies suggesting additive effects on tendon and muscle repair. No human combination-therapy trial data exists.

References

1. Sikiric P, et al. (2018). Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications. Curr Neuropharmacol. 16(10):1401-1425.
2. Chang CH, et al. (2011). The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 110(3):774-780.
3. Gwyer D, et al. (2019). Gastric pentadecapeptide body protection compound BPC 157 and its role in healing disorders. Front Pharmacol. 10:1523.
4. Tkalcevic VI, et al. (2007). Enhancement by PL 14736 of granulation and angiogenesis in rats. Eur J Pharmacol. 570(1-3):212-221.
5. Seiwerth S, et al. (2014). BPC 157 and Standard Angiogenesis. Curr Pharm Des. 20(7):1126-1135.
6. Staresinic M, et al. (2006). Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon. J Orthop Res. 21(6):976-983.
7. Vukojevic J, et al. (2018). Pentadecapeptide BPC 157 and the central nervous system. Prog Neuropsychopharmacol Biol Psychiatry. 84(Pt B):363-372.